It’s Time To Focus On The Long Run With Emergent BioSolutions Inc. (EBS) stock

Emergent BioSolutions Inc. (NYSE: EBS) closed the day trading at $13.11 down -3.10% from the previous closing price of $13.53. In other words, the price has decreased by -$0.42 from its previous closing price. On the day, 501174 shares were traded. EBS stock price reached its highest trading level at $14.20 during the session, while it also had its lowest trading level at $13.03.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…



For a better understanding of EBS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.63 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.02. For the most recent quarter (mrq), Quick Ratio is recorded 2.10 and its Current Ratio is at 4.20. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.71.

Upgrades & Downgrades

The Benchmark Company Upgraded its Hold to Buy on January 20, 2022, while the target price for the stock was maintained at $77.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 25 when Richard Ronald sold 1,912 shares for $11.94 per share. The transaction valued at 22,829 led to the insider holds 19,837 shares of the business.

Zoon Kathryn C sold 1,173 shares of EBS for $36,973 on Jun 09. The Director now owns 19,654 shares after completing the transaction at $31.52 per share. On May 24, another insider, Zoon Kathryn C, who serves as the Director of the company, sold 1,996 shares for $35.53 each. As a result, the insider received 70,918 and left with 12,381 shares of the company.

Valuation Measures:

As of this moment, Emergent’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.99, and their Forward P/E ratio for the next fiscal year is 17.09. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.42 while its Price-to-Book (P/B) ratio in mrq is 0.45.

Stock Price History:

Over the past 52 weeks, EBS has reached a high of $47.71, while it has fallen to a 52-week low of $10.61. The 50-Day Moving Average of the stock is 12.40, while the 200-Day Moving Average is calculated to be 24.64.

Shares Statistics:

Over the past 3-months, EBS traded about 1.01M shares per day on average, while over the past 10 days, EBS traded about 900.33k shares per day. A total of 49.90M shares are outstanding, with a floating share count of 44.81M. Insiders hold about 0.50% of the company’s shares, while institutions hold 84.60% stake in the company. Shares short for EBS as of Oct 13, 2022 were 2.03M with a Short Ratio of 5.57M, compared to 2.05M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.07% and a Short% of Float of 6.45%.

Earnings Estimates

Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of -$0.06 for the current quarter, with a high estimate of $0.26 and a low estimate of -$0.48, while EPS last year was -$0.36. The consensus estimate for the next quarter is $0.76, with high estimates of $1.06 and low estimates of $0.39.

Analysts are recommending an EPS of between $0.3 and -$0.22 for the fiscal current year, implying an average EPS of $0.02. EPS for the following year is $2.03, with 5 analysts recommending between $5.39 and $0.54.

Revenue Estimates

7 analysts predict $268.3M in revenue for the current quarter. It ranges from a high estimate of $320M to a low estimate of $247M. As of the current estimate, Emergent BioSolutions Inc.’s year-ago sales were $329M, an estimated decrease of -18.40% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $378.53M, a decrease of -47.70% less than the figure of -$18.40% in the same quarter last year. There is a high estimate of $429M for the next quarter, whereas the lowest estimate is $345M.

A total of 7 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $1.25B, while the lowest revenue estimate was $1.16B, resulting in an average revenue estimate of $1.2B. In the same quarter a year ago, actual revenue was $1.79B, down -33.20% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $1.23B in the next fiscal year. The high estimate is $1.28B and the low estimate is $1.13B. The average revenue growth estimate for next year is up 2.90% from the average revenue estimate for this year.